Literature DB >> 34996131

Key changes to the World Health Organization (WHO) classification of female genital tumours introduced in the 5th edition (2020).

W Glenn McCluggage1, Naveena Singh2, C Blake Gilks3.   

Abstract

An updated World Health Organization (WHO) classification of female genital tumours was published in autumn 2020. We discuss the major new additions to and changes from the prior 2014 classification with a discussion of the reasons underlying these. A feature of the new classification is the greater emphasis on key molecular events with integration of morphological and molecular features. Most of the major changes from the prior classification pertain to uterine (corpus and cervix) and vulval tumours, but changes in all organs are covered.
© 2022 John Wiley & Sons Ltd.

Entities:  

Keywords:  World Health Organization; cervix; endometrium; female genital tract; tubo-ovarian

Mesh:

Year:  2022        PMID: 34996131     DOI: 10.1111/his.14609

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  3 in total

1.  Comprehensive Approach to Genomic and Immune Profiling: Insights of a Real-World Experience in Gynecological Tumors.

Authors:  Iván Prieto-Potin; Franklin Idrovo; Ana Suárez-Gauthier; María Díaz-Blázquez; Laura Astilleros-Blanco de Córdova; Cristina Chamizo; Sandra Zazo; Nerea Carvajal; Almudena López-Sánchez; Sandra Pérez-Buira; Carmen Laura Aúz-Alexandre; Rebeca Manso; Jenifer Plaza-Sánchez; Virginia de Lucas-López; Nuria Pérez-González; Sara Martín-Valle; Ion Cristóbal; Victoria Casado; Jesús García-Foncillas; Federico Rojo
Journal:  Diagnostics (Basel)       Date:  2022-08-06

2.  Recurrent uterine inflammatory myofibroblastic tumor previously managed as leiomyosarcoma has sustained response to alectinib.

Authors:  Erica V Carballo; Tra V Pham; Gulisa Turashvili; Krisztina Hanley; Kristen D Starbuck; Jane L Meisel
Journal:  Gynecol Oncol Rep       Date:  2022-08-17

3.  Case report: Strategies for improving outcomes in patients with primary ovarian small-cell neuroendocrine carcinoma.

Authors:  YingYing Li; Yueling Wu; Ying Zhang; Xiaofang Li
Journal:  Front Oncol       Date:  2022-09-23       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.